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In 2015, 10.4 million people were diagnosed 
with tuberculosis (TB)1 and 2.1 million 
people tested positive for HIV.2 Over 
two-thirds of new TB and HIV infections 
are in lower income and middle-income 
countries in sub-Saharan Africa and Asia. 
Together, TB and HIV cause over 2.5 million 
deaths each year,1 2 and immeasurable social 
calamities. Key among these is widespread 
stigmatisation incited by their deep-set asso-
ciation with poverty, social marginalisation, 
risk of transmission and death, and perpetu-
ated to varying degrees by subversive policies 
and practices.3 4 The stigma is doubly worse 
for the 1.2 million people world over who live 
with both infections.1 5 
Since its outset in the 1980s, people with 
HIV and health activists have galvanised 
HIV stigma into a force for social change.6 
They have willed action against prejudi-
cial practices with tangible transformative 
effects at the individual, policy and political 
level.7 HIV-related discrimination has been 
confronted with empowerment. Policies such 
as those for HIV testing, treatment, counsel-
ling, medication access and employment of 
persons with HIV seek to affirm and uphold 
the rights of those affected by HIV.8 When the 
fulfilment of human rights has fallen short in 
practice, HIV activists have used rights-based 
approaches to overcome stigma and discrimi-
nation, and organise for change.
The TB community has always recognised 
the stigma that surrounds the disease but has 
done far less to confront it.9 10 The risk and 
fear of transmission of the airborne infec-
tion are often raised in defence of policies 
and practices that prioritise the well-being of 
the collective public over that of individual 
patients.11 Persons with TB or presumed 
to have TB continue to be subjected to 
stigmatising language (eg, ‘TB suspects’, 
‘defaulters’), mandatory screening, testing 
and disease notification systems that lack 
privacy, contact investigations that label 
index patients, airborne respiratory isolation 
that prolongs their social isolation, directly 
observed treatment (DOT) that impedes 
individual autonomy, and in rare but relevant 
cases, legal detention and even incarceration 
of those who refuse or stop treatment.7 11 12 
As these practices continue to be applied in 
biomedical, public health-oriented ways, they 
fuel the social exclusion of people with TB, 
and reify assumed conflicts between public 
health and patient rights.7 13
People with multidrug-resistant or exten-
sively drug-resistant TB (M/XDR-TB), 
the most clinically severe forms of TB, are 
often the most judged and stigmatised.14 
As non-adherence to TB treatment is 
considered to be one cause of developing 
drug resistance, patients with M/XDR-TB 
are routinely reprimanded for having been 
‘non compliant’ to previous treatments with 
neglect to the sociomedical environment in 
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Summary box
 ► The global tuberculosis (TB) and HIV epidemics are 
worsened by stigmatisation that is incited by their 
association with poverty, social marginalisation, risk 
of transmission and death, and may be perpetuated 
by subversive policies and practices.
 ► The HIV community has successfully rallied forces 
to challenge the stigmatisation of people with 
HIV, through collective, grassroots human rights 
movements that have led to tangible shifts in 
policy. The TB community has not adequately 
contested programmatic norms that reinforce TB 
stigma.
 ► The TB community not adequately contested 
age-old programmatic norms that reinforce the 
stigmatisation of people with or affected by TB.
 ► Raising awareness about TB stigma is insufficient 
to mitigate stigma. The TB community needs 
consciousness raising, a form of activism where 
people with and affected by TB come together to 
share their experiences, identify common struggles 
and begin collectively organising to change harmful 
practices.
 ► TB science can be used to affirm the rights and 
dignity of people with TB. Common TB policies and 
practices can be modified to reduce TB stigma, 
informed by lessons from HIV activism.
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Table 1 Recommendations to modify practices that may compound stigmatisation of patients with tuberculosis (TB)
TB policy or 
practice Strategies to mitigate stigma
TB screening 
and testing
 ► Inform and counsel patients about TB and/or differential diagnoses pre and post screening and testing
 ► Protect patient confidentiality (eg, share test results in private)
 ► Advise patients of their right to access treatment
TB notification  ► Protect confidentiality of TB test results and patient anonymity (eg, use unique patient IDs, or draw on 
local HIV reporting methods)
 ► Institute safeguards to ensure that TB test status does not affect a person’s employment status, 
immigration status or qualification for other government benefits or services (eg, implement firewall 
policies between public health services and other state functions such as immigration and border control)
Contact tracing  ► Integrate TB-related health literacy and counselling into contact investigations (eg, family counselling, 
support patients in ways to disclose their illness)
 ► Protect patient confidentiality (eg, avoid naming or labelling the index patient wherever possible)
 ► Provide preventive therapy where warranted (ie, ensure that a TB diagnosis is followed by the option to 




 ► Inform and counsel patients about TB transmission risks and measures to reduce these risks
 ► Normalise face mask use and emphasise its capacity to protect patients in addition to contacts
 ► Test sputum routinely to identify conversion/non-infectivity, to enable early discharge from isolation, and 
use rapid tests such as Xpert MTB/RIF to facilitate this
 ► Identify safe peer and social support networks to mitigate social isolation
TB treatment 
initiation
 ► Inform and counsel patients about TB treatment, including duration, potential side effects, expected 
benefits, availability of free treatment and the importance of adherence
 ► Promote equitable access to newer, safer, shorter treatment regimens
 ► Engage patients in decisions regarding auxiliary therapy, where possible (eg, management of adverse 
effects, mental health, nutritional supplementation)
 ► Refer patients to services and resources to facilitate adequate support for adherence, including referral to 
champion patients and TB survivors
 ► Advise patients of their right to access treatment as opposed to just their mandate to initiate and adhere to 
therapy
 ► Establish systems that respect patient decisions to access TB services from their preferred provider and 
maintain continuity of care (eg, public–private health partnerships, integration of TB and HIV services)
TB treatment 
monitoring
 ► Build TB treatment literacy to support self-administration
 ► Implement adherence promotion strategies that are feasible and acceptable to patients (eg, phone 
reminders, smart pill boxes, peer networks)
 ► Promote mechanisms to protect patients’ employment and enable access to social security during TB 
treatment
 ► Facilitate safe reintegration of patients into social and work settings to foster social well-being and 
financial independence (eg, by sensitising employers and families to TB)
 ► Assess palliative care needs and resources for patients who may be incurable, and their caregivers
TB research 
activities
 ► Involve research participants and other community members and stakeholders in the research 
development and dissemination process (eg, following the recommendations of the Good Participatory 
Practices for TB Drug Trials)
 ► Create a community advisory group to inform the research process and ensure that research practices and 






 ► Raise global consciousness by connecting TB-affected communities through media and other forms of 
public representation (eg, via stories and images of healthy TB survivors rather than those that reinforce 
negative stereotypes against groups most affected by TB)
 ► Disrupt the current narrative underlying practices that may be stigmatising (eg, reframe TB screening and 
contact tracing practices as empowering so that an index patient gains control of his/her illness and uses 
this knowledge to protect others)
 ► Use TB science to affirm rather than neglect the rights of patients with TB (eg, emphasise when a patient 
becomes non-infectious just as vigorously as his/her infectious state was emphasised)
 ► Sensitise employers to support employees with TB and promote employment of TB survivors
 ► Build spaces for consciousness raising by bringing together people affected by TB to share their 
experiences, identify common challenges, and organise to change practices that reify stigma or impede 
patient-centred care (eg, through peer networks and advocacy forums)
 ► Routinely invite TB survivors to speak at (even open) TB conferences and meetings, to acknowledge their 
suffering and to give them a voice in the mainstream TB community
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which adherence transpires—one that is fraught with 
low-quality health systems, patient–provider mistrust, 
primary drug resistance, and poor access to diagnostic 
tools, new drugs, treatment literacy, social protections 
and infection control.15 Similarly, in many low-incidence 
countries, specific population groups such as migrants 
and refugees are portrayed as a public health threat and 
blamed for being carriers of TB.16 We are in need of a 
counternarrative to debunk timeworn arguments that 
continue to hold individual patients culpable for popula-
tion-level failures and outcomes.
In recent years, key actors in the TB community, such 
as the Stop TB Partnership, Treatment Action Group, TB 
PROOF, Global Coalition of Tuberculosis Activists and 
KNCV Tuberculosis Foundation, to name just a few, are 
creating meaningful change in the praxis of TB care with 
potential effects on stigma reduction.11 13 17 18Terms that 
reinforce negative stereotyping of people with TB are 
being extricated from clinicians’ and researchers’ vocab-
ularies.11 The hardline DOT approach is gradually ceding 
to patient-centred approaches that emphasise commu-
nity engagement, patient counselling and structural aid 
in adherence promotion, even a murmur of palliative 
care for those with incurable disease.15 Governments and 
industry are being held accountable for implementing 
new technologies to ensure equitable access to the fruits 
of scientific advancement.13 Global health ambassadors 
including TB survivors are raising awareness about TB on 
a societal level through messages that affirm the dignity 
of people with TB rather than amplify the fear of TB.11
But this gradual advocacy movement of awareness raising, 
while necessary, is insufficient to tackle the structural 
drivers of stigma. The TB community needs conscious-
ness raising, a form of activism that connects disparate 
experiences of discrimination and disenfranchisement, 
and the systems and structures that abet them, across 
time and space.19 Consciousness raising can take place 
when people with and affected by TB come together to 
share their experiences, identify common struggles and, 
based on this foundation, begin collectively organising 
to change practices that are stigmatising and potentially 
harmful. The resulting solidarity, characteristics of which 
we see in communities affected by HIV across the globe, 
and who are linked despite differences in race, sex and 
economy, can lay the foundation for more lasting social 
change. Replacing images of radiographs or mycobac-
teria, for example, with the well faces of those who have 
braved TB may help connect communities and humanise 
TB. Implementing a comprehensive framework for TB 
treatment literacy may allow counselling efforts to mature 
from piecemeal to universal practice. Framing contact 
investigations as a way for patients with TB to protect, 
rather than disrupt, their position in the household may 
avoid alienating index cases. TB science and the methods 
by which it is implemented can help to accelerate this 
transformation to better affirm the rights and dignity 
of people with TB. Knowledge of TB transmission most 
often used to isolate—and at times incriminate—patients 
can be harnessed to emphasise the stage at which patients 
become non-infectious.
Destigmatising TB is well aligned with ‘zero suffering’, 
a prominent goal of the WHO’s new End TB Strategy 
distinct from the goal of zero infections and zero 
deaths.20 One step towards alleviating patient suffering 
is to revisit policies and practices that fuel TB stigma and 
raise global consciousness for an inclusive and non-stig-
matising approach to TB care (see table 1 for our recom-
mendations). It is time we combated stagnant policies 
and complacency that diminish the social value of people 
with TB, and indeed feed into derogation of the epidemic 
itself in the hierarchy of global health challenges.21 As 
actors in the TB community continue working bottom-up 
to create micro forces of change, the healthcare system, 
scientific community, industry and donor agencies must 
sign on to stimulate a tangible shift through collective 
action and collective voice—one that is loud enough for 
10 million voices to be heard.
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